LAUSR

BACKGROUND Evidence on tralokinumab treatment for moderate-to-severe atopic dermatitis (AD) in daily practice is limited. OBJECTIVES To report first experience with tralokinumab treatment in daily practice in AD patients. METHODS In this observational prospective study, AD patients who received tralokinumab treatment in the context of routine care at the Erasmus Medical Centre were included between November 2021 and February 2022. This included 28 patients that had previously been treated with dupilumab, and 14 patients that had been treated with a JAK inhibitor (JAKi). The Investigator Global Assessment (IGA; 0-4) and the Numeric Rating Scale peak pruritus (NRS itch 7d: 0-10) during the past seven days, adverse events, and reasons for discontinuation were analyzed A good clinical response was defined as any decrease in IGA and NRS itch 7d and if a patient was satisfied with the treatment and wishes to continue with the therapy. RESULTS In total, 37 patients were treated with tralokinumab. Twenty-two (59%) patients showed good response to tralokinumab treatment. Fifteen (41%) patients discontinued treatment due to inadequate AD control or adverse events. Treatment-related adverse events were mild in most patients. Half of the patients who failed dupilumab had good clinical response on tralokinumab. CONCLUSIONS Tralokinumab was found effective in most patients in this difficult-to-treat, severe AD daily practice cohort. Interestingly, tralokinumab was also found to be effective in 50% of patients that previously experienced insufficient response or adverse events with dupilumab.